159 completed, 72 unknown, 33 terminated, 18 withdrawn. 68 Phase 2, 45 Phase 3, 44 Phase 1, 42 Not applicable, 12 Phase 4.
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations mRNA-1273, mRNA-1283 - SARS-CoV-2 | Phase 4 | Recruiting | ModernaTX, Inc. | 300 | 2026-10-09 | 2026-10-27 |
| A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease Secutrelvir, Placebo - SARS-CoV-2 | Phase 3 | Recruiting | Shionogi | 2000 | 2026-09-14 | 2026-10-26 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age mRNA-1283, mRNA-1273 - SARS-CoV-2 | Phase 2 | Not yet recruiting | ModernaTX, Inc. | 300 | 2026-09-01 | 2026-09-09 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) mRNA-1273, mRNA-1283, Placebo - SARS-CoV-2 | Phase 4 | Active not recruiting | ModernaTX, Inc. | 30000 | 2025-11-26 | 2026-09-28 |
| Secondary Databased Post-marketing Surveillance Study of BNT162b2 Tozinameran (BNT162b2), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5) - COVID-19, SARS-CoV-2 | Completed | Pfizer | 14302529 | 2025-04-23 | 2026-07-10 | |
| A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B - Influenza, SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 1320 | 2025-03-07 | 2025-10-20 |
| ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19) ACE2 Chewing Gum, Placebo Chewing Gum - SARS-CoV-2 | Phase 1 / Phase 2 | Withdrawn | University of Pennsylvania | 2025-02-01 | 2025-03-30 | |
| SARS-CoV-2 Safety Study for the Treatment of COVID-19 HIV, Malignant Neoplasms Safety Study for the Treatment of Neoplasms - SARS-CoV-2 | Phase 2 | Withdrawn | DHA Coffee Co., Ltd | 2025-01-28 | 2025-09-04 | |
| Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay Credo POCT Device - SARS-CoV-2, COVID-19 | Completed | Credo Diagnostics Biomedical Pte. Ltd. | 1268 | 2024-11-01 | 2026-03-18 | |
| Viral Infection of HSPC Impacts Hematopoiesis HIV-1, SARS-CoV-2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 45 | 2024-10-25 | 2025-03-20 | |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) Placebo comparator, PRS CK STORM - SARS-CoV-2, Influenza, Human | Phase 1 / Phase 2 | Recruiting | PEACHES BIOTECH | 50 | 2024-10-02 | 2026-06-10 |
| Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients combination therapy, SOC - COVID-19, SARS-CoV-2 | Not applicable | Not yet recruiting | National Taiwan University Hospital | 40 | 2024-09-21 | 2024-09-25 |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations mRNA-1273 Variant-containing Formulation - SARS-CoV-2 | Phase 4 | Recruiting | ModernaTX, Inc. | 1144 | 2024-09-09 | 2026-03-27 |
| A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) mRNA-1083 - Influenza, SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 931 | 2024-07-15 | 2026-10-08 |
| A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults Investigational mRNA-1273.815, Licensed Spikevax Vaccine - SARS-CoV-2 | Phase 3 | Completed | ModernaTX, Inc. | 217 | 2024-04-08 | 2025-05-25 |
| Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years COMIRNATY intramuscular injection - SARS-CoV-2, COVID-19 | Completed | Pfizer | 25 | 2024-03-06 | 2025-07-14 | |
| PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 Upamostat, Placebo (PO) - SARS-CoV-2 | Phase 2 | Completed | Henry M. Jackson Foundation for the Advancement of Military Medicine | 92 | 2024-01-29 | 2026-04-17 |
| Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination 30μg dose of LYB002V14, 60μg dose of LYB002V14, placebo - SARS-CoV-2, COVID-19 Vaccine | Phase 1 | Unknown | Guangzhou Patronus Biotech Co., Ltd. | 120 | 2023-12-26 | 2023-12-26 |
| The Impact of the COVID-19 Pandemic on the Patient in Need of an Intervention Surgical Procedures, Operative, COVID-19 | Completed | University Medical Center Groningen | 5277 | 2023-11-01 | 2026-01-07 | |
| Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data Pfizer-BioNTech COVID-19 mRNA vaccine - SARS-CoV-2, COVID-19 | Terminated | Pfizer | 1 | 2023-10-23 | 2026-09-15 |
Showing 20 of 300. Sign in to see all of them.
COVID-19 (205) · Coronavirus Infections (69) · Virus Diseases (25) · Severe Acute Respiratory Syndrome (15) · Influenza, Human (10) · Respiratory Distress Syndrome (9) · Anxiety Disorders (5) · Respiratory Insufficiency (5) · Pneumonia (4) · Anosmia (3) · Communicable Diseases (3) · Cytokine Release Syndrome (3) · Depression (3) · Hypoxia (3) · Infections (3)
Infections (214) · RNA Virus Infections (214) · Respiratory Tract Diseases (214) · Coronaviridae Infections (211) · Nidovirales Infections (211) · Respiratory Tract Infections (210) · Lung Diseases (206) · Pneumonia, Viral (204) · Pneumonia (202) · Virus Diseases (190) · Coronavirus Infections (142) · Pathological Conditions, Signs and Symptoms (26) · Pathologic Processes (19) · Respiration Disorders (13) · Signs and Symptoms (12)
2019-nCoV Vaccine mRNA-1273 (16) · Hydroxychloroquine (12) · CVnCoV COVID-19 vaccine (11) · Saline Solution (7) · Sodium Chloride (7) · BNT162 Vaccine (6) · Blood Specimen Collection (6) · mRNA-1273.214 COVID-19 vaccine (6) · Azithromycin (5) · Standard of Care (5) · mRNA Vaccines (4) · remdesivir (4) · Ascorbic Acid (3) · ChAdOx1 nCoV-19 (3) · LVRNA009 COVID-19 vaccine (3)
ModernaTX, Inc. (33) · AIM Vaccine Co., Ltd. (12) · CureVac (6) · Pfizer (6) · University Hospital, Montpellier (6) · Assistance Publique - Hôpitaux de Paris (5) · AstraZeneca (4) · University of Minnesota (4) · Assiut University (3) · Genexine, Inc. (3) · GlaxoSmithKline (3) · University Hospital, Strasbourg, France (3) · Arcturus Therapeutics, Inc. (2) · Argorna Pharmaceuticals Co., LTD (2) · BioNTech SE (2)
United States (106) · France (32) · China (26) · Germany (14) · Belgium (11) · Spain (11) · Brazil (10) · United Kingdom (10) · Mexico (9) · South Korea (9) · Peru (8) · Argentina (7) · Australia (7) · Canada (7) · South Africa (7)
Huan Zhou (5) · Qiang Wu (5) · Aliae Mohamed-Hussein, MD (2) · Dazhi Zhang, M.D. (2) · Fan Zhang (2) · Giovanni Martinelli, Prof. (2) · Guiling Chen (2) · Jun Yong Choi, MD (2) · JungWon Woo, Ph.D. (2) · Lanjuan Li (2) · Xiang Lu (2) · Yuwen Su (2)
PMID 34473343, PMID 32788708, PMID 34350582, PMID 36202997, PMID 36695483, PMID 37385888, PMID 38518789, PMID 39225478, PMID 39481241, PMID 11225528, PMID 11505791, PMID 16490989, PMID 16940336, PMID 17099299, PMID 19887665, PMID 20160606, PMID 20354090, PMID 21366476, PMID 21435708, PMID 23017003, PMID 23433693, PMID 24693893, PMID 28802696, PMID 29420257, PMID 29633177, PMID 29680828, PMID 29757717, PMID 30519584, PMID 30566567, PMID 30639191, PMID 31761015, PMID 32031570, PMID 32047895, PMID 32083985, PMID 32109013, PMID 32155105, PMID 32159775, PMID 32179701, PMID 32217624, PMID 32293449, PMID 32326426, PMID 32382733, PMID 32399710, PMID 32423584, PMID 32425001, PMID 32448345, PMID 32461413, PMID 32493478, PMID 32503173, PMID 32505069
2023 (2), 5UM1AI068614-14 (2), 3UL1TR002243-04S3 (1), P20GM104417 (1), P51OD011106 (1), R01AI136514 (1), R33AG057395 (1)